Abstract: Disclosed is a method of inhibiting growth of a melanoma cancer cell. The method includes contacting the melanoma cancer cell with an effective amount of a composition and the composition contains polymethoxyflavone. The polymethoxyflavone can be applied in an amount of 0.1 ?mol/L-1000 ?mol/L. A method of treating a subject having melanoma with the above discussed composition is also included.

Abstract: Provided is a papillomavirus chimeric protein, the skeleton thereof being a papillomavirus L1 protein or a mutant thereof, at least one human papillomavirus 33-type L2 protein or mutant polypeptide thereof being embedded on the skeleton. The present papillomavirus chimeric protein can be used for preparing a vaccine for preventing papillomavirus infections and infection induced disease.

Abstract: The present invention provides a compound of Formula I, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.

Abstract: Disclosed are compounds of Formula A, or a salt thereof, where Q, X, R1 and R2 are as defined herein, which compounds have properties for inhibiting Na 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain (acute, post-operative, neuropathic), or cough or itch disorders using the same.

Abstract: An embodiment of the present invention discloses a travel assisting method, including: extracting trip information from content saved in a terminal and saving the extracted trip information in a trip list; selecting the trip information from the trip list, automatically connecting to a preset network address or a preset server address, and searching by using part or all of content of each piece of the selected trip information as a key word, so as to obtain assisting information corresponding to the trip information; and generating prompting information. Correspondingly, an embodiment of the present invention further discloses a terminal. The present invention enables the terminal to automatically provide effective reference information for a user according to a trip of the user, solving the problem that an operation is troublesome and time-consuming when the user obtains trip-related assisting information by using the terminal.

Abstract: The present invention relates to a compound of formula I, a stereoisomer, a prodrug, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, and a process for preparing the same, a pharmaceutical composition comprising the same, and use of the compound in the preparation of medicine preventing and treating tumors, wherein the substituents are as defined in the specification.

Abstract: The invention discloses a terminal backup and recovery method. When in backup, a user interface is provided at a terminal side first, so as to provide, according to a preset display policy, different backup categories for a user to select, wherein the different backup categories comprise different backup objects. Then, according to a backup category and object selected by the user, at the terminal side, a terminal file corresponding to the backup object is backed up at a cloud server according to a preset backup policy. When in recovery, according to a recovery category and object selected by the user, a file already backed up by the terminal/user and corresponding to the backup object is determined at the cloud server, and according to a preset recovery policy, corresponding recovery is executed at the terminal side by using the backed-up file. The invention provides classified backup and recovery, and increases the speed of backup and recovery.

Abstract: Methods for treating various cancers by administering one or more compounds that target the dimeric protein survivin are disclosed. Pharmaceutical compositions containing such compounds are also disclosed, along with general methods of identifying anti-cancer compounds that target oncogenic dimeric proteins. Exemplary compounds that can be used in the disclosed methods of treatment and pharmaceutical compositions have the chemical structure.

Abstract: Systems and methods are described herein for analyzing the performance of a communications network (e.g., a mobile telecommunications network) using customer-centric and/or subscriber-centric data and information. In some embodiments, the systems and method may determine key performance indicators for a communications network by accessing call detail records from multiple communications network sources, generating a database of one or more customer stats table (CSTs) based on the accessed call records, wherein the CSTs include records for each individual customers of the communications network, and determining one or more key performance indicators (KPIs) for the overall network based on the records stored by the one or more customer stats tables.

Abstract: Systems and methods are described herein for analyzing the performance of a communications network (e.g., a mobile telecommunications network) using customer-centric and/or subscriber-centric data and information. In some embodiments, the systems and method may determine key performance indicators for a communications network by accessing call detail records from multiple communications network sources, generating a database of one or more customer stats table (CSTs) based on the accessed call records, wherein the CSTs include records for each individual customers of the communications network, and determining one or more key performance indicators (KPIs) for the overall network based on the records stored by the one or more customer stats tables.

Abstract: Systems and methods are described herein for determining dropped call rates (DCR) for various communications networks, such as IP Multimedia Networks (IMS), which include Voice over LTE (VoLTE) networks. For example, the systems and methods utilize data (e.g. abnormal cause codes) generated by layers of the IMS networks, such as a Session Initiation Protocol (SIP) layer of the IMS network, when determining dropped call rates for IMS networks.

Abstract: A method for smelting magnesium quickly and continuously includes: preparing dolomite or magnesite with reductants and fluorite at a predetermined ratio, uniformly mixing the prepared ingredients to obtain pellets, and calcining the obtained pellets in an argon or nitrogen atmosphere; continuously feeding the high-temperature calcined pellets (without being cooled) under argon protection into a reduction furnace, and performing a high-temperature reduction reaction in a flowing argon atmosphere to obtain high-temperature magnesium steam; and enabling the high-temperature magnesium steam to be carried out of the high-temperature reduction furnace by an argon flow, and performing condensation to obtain metal magnesium. The present invention eliminates a vacuum system and a vacuum reduction tank, so that quick and continuous production of the metal magnesium is realized, the reduction time is shortened to 90 min or less, and the recovery rate of magnesium is increased to 88% or more.

Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., lung cancer, breast cancer, leukemia, lymphoma, melanoma, multiple myeloma, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase (e.g. a protein kinase (e.g. a cyclin-dependent kinase (CDK) (e.g. CDK7, CDK12, or CDK13) or a lipid kinase such as a phosphatidylinositol-5-phosphate 4-kinase (PIP4K) (e.g.

Abstract: Apparatuses and methods are disclosed for cluster switching. An exemplary method may include synchronizing original data on a first cluster to a second cluster after starting to switch clusters. A priority of the original data on the second cluster is set to a lower priority. The method may also include responding to a write operation request on the second cluster in the period of synchronizing the original data on the first cluster to the second cluster. A priority of new data corresponding to the write operation request is set to a higher priority. A version of data with a higher priority can overwrite another version of data. The method may further include responding to the write operation request on the second cluster after synchronizing the original data on the first cluster to the second cluster.

Abstract: In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

Abstract: The invention discloses a flexible conductive diaphragm comprising at least one conductive film, and the conductive film comprises a flexible support layer (1), a flexible sensitive layer (2) overlapped on the flexible support layer (1), a flexible conductive layer (3) overlapped on the flexible sensitive layer (2), and an electrode (4) electrically connected with the flexible conductive layer (3). The invention further discloses a method for preparing the flexible conductive diaphragm, and a flexible vibration sensor based on the flexible conductive diaphragm. With the combination of the techniques such as the flexible material, the nano-material and the arrayed micro-structure, the flexible vibration sensor of the present invention has the characteristics of high sensitivity, low preparation cost, light weight, small thickness, small size, and being foldable and flexible, and can be applied in wearable or adherable electronic devices.

Abstract: The present invention provides compounds of Formula (I) and pharmaceutical compositions comprising compounds of Formula I, and methods for using compounds of Formula I for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes.

Abstract: The present invention provides a compound of Formula I, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.

Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.